Clinical Trial Update: A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating SAR445514 in relapsed/refractory multiple myeloma and light-chain amyloidosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis
• Multiple Myeloma

Drugs mentioned

• SAR445514

Snippet

Sponsor: Sanofi | Conditions: Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | Phase 1, Phase 2 | Status: TERMINATED